Fig. 4. Stable CTSB knockdown suppresses tumor growth of RCC xenografts—an effect rescued by wild type but not mutant CTSB. Pharmacological inhibition of CTSB in combination with sunitinib is superior to sunitinib monotherapy.

Tumor growth curves and tumor growth coefficients and P-values are shown in tables above curves, with table cells colored as per linear scale color gradient to represent P-values. Non-significant values are displayed with gray shading. a tumor growth in the 786-O model of LKO vs shCTSB2. shCTSB2 + CTSB^wt/hi xenografts exhibited partial rescue from the growth-inhibitory effects of shCTSB, whereas shCTSB + mutant CTSB^N298A xenografts failed to exhibit rescue of the growth suppression seen with shCTSB. b Effects of pharmacologic CTSB inhibition in the A498 tumor model. Tumor growth was reduced by single agent Ca074-Me but to a lesser extent than with sunitinib alone. The combination of Ca074-Me and sunitinib showed stronger growth inhibition than did either single agent